Third Harmonic Bio Inc. (THRD)
3.52
0.03 (0.86%)
At close: Mar 28, 2025, 3:57 PM
3.51
-0.14%
After-hours: Mar 28, 2025, 04:02 PM EDT
Company Description
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases.
It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications.
The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019.
Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Third Harmonic Bio Inc.
| Country | United States |
| IPO Date | Sep 14, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Natalie C. Holles |
Contact Details
Address: 300 Technology Square Cambridge, Massachusetts United States | |
| Website | https://www.thirdharmonicbio.com |
Stock Details
| Ticker Symbol | THRD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001923840 |
| CUSIP Number | 88427A107 |
| ISIN Number | US88427A1079 |
| Employer ID | 83-4553503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Natalie C. Holles | Chief Executive Officer & Director |
| Jennifer Dittman | Chief Operating Officer |
| Christopher Murphy | Chief Financial & Business Officer |
| Dennis Dean Ph.D. | Chief Non-Clinical Development Officer |
| Dr. Christopher J. Dinsmore Ph.D. | Chief Scientific Officer |
| Dr. Edward R. Conner M.D. | Chief Medical Officer |
| Julie Person | Chief Administrative Officer |
| Ommer Chohan | Treasurer & Secretary |
| Steven P. Sweeney | Senior Vice President of Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | S-8 | Filing |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 05, 2025 | 4 | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Feb 11, 2025 | 8-K | Current Report |
| Jan 22, 2025 | SCHEDULE 13D/A | [Amend] Filing |